Mid
A
AVBPAI Stock Diagnostic Report
ArriVent stock tumbles 60% after trial misses primary endpoint
ArriVent's stock price plunged 60% after its clinical trial failed to meet the primary endpoint.
View Source Article ↗AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time